{"filing":{"accession_number":"0001809519-26-000151","cik":"0001809519","ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"gdrx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/gdrx-20260805.htm"},"events":[{"id":25260,"run_id":22921,"accession_number":"0001809519-26-000151","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"GoodRx disclosed its financial results for Q2 2026 (three and six months ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes revenue of $200.4 million, net income of $8.5 million, adjusted EBITDA of $63.7 million, and raised full-year 2026 guidance for both revenue ($790–$805 million) and adjusted EBITDA ($240–$250 million). This is a standard quarterly earnings announcement material to investors.","company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26038,"accession_number":"0001809519-26-000151","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"GoodRx disclosed its financial results for Q2 2026 (three and six months ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes revenue of $200.4 million, net income of $8.5 million, adjusted EBITDA of $63.7 million, and raised full-year 2026 guidance for both revenue ($790–$805 million) and adjusted EBITDA ($240–$250 million). This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:41.177494+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26038,"accession_number":"0001809519-26-000151","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"GoodRx disclosed its financial results for Q2 2026 (three and six months ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes revenue of $200.4 million, net income of $8.5 million, adjusted EBITDA of $63.7 million, and raised full-year 2026 guidance for both revenue ($790–$805 million) and adjusted EBITDA ($240–$250 million). This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:41.177494+00:00","company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","filing_date":"2026-08-05"}]}